Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Alexia Patroni"'
Autor:
Jérôme Alexandre Denis, Alexia Patroni, Erell Guillerm, Dominique Pépin, Naoual Benali-Furet, Janine Wechsler, Gilles Manceau, Maguy Bernard, Florence Coulet, Annette K. Larsen, Mehdi Karoui, Jean-Marc Lacorte
Publikováno v:
Molecular Oncology, Vol 10, Iss 8, Pp 1221-1231 (2016)
In colorectal cancer (CRC), KRAS mutations are a strong negative predictor for treatment with the EGFR‐targeted antibodies cetuximab and panitumumab. Since it can be difficult to obtain appropriate tumor tissues for KRAS genotyping, alternative met
Externí odkaz:
https://doaj.org/article/c3706c07b9d94c6ca64428ed30c982ae
Publikováno v:
Colorectal Disease. 19:O377-O385
Aim To assess the prognostic influence of the circumferential resection margin (CRM) exact value after total mesorectal excision (TME) for mid or low rectal cancer. Methods All patients (n=321), who underwent TME from 2005 and 2013 where identified f
Publikováno v:
Soins. Gerontologie. 23(132)
Colorectal cancer risk factors increase with age, comorbidities, delayed diagnosis, obstruction, emergency and frailty. Surgery is the standard treatment as the survival rate for this pathology is the same as in young patients. It would appear that t
Publikováno v:
Soins Gérontologie. 23:24-25
Colorectal cancer risk factors increase with age, comorbidities, delayed diagnosis, obstruction, emergency and frailty. Surgery is the standard treatment as the survival rate for this pathology is the same as in young patients. It would appear that t
Autor:
Alexia Patroni, Janine Wechsler, Erell Guillerm, Maguy Bernard, Jean-Marc Lacorte, Mehdi Karoui, Florence Coulet, Jérôme Alexandre Denis, Naoual Benali-Furet, Gilles Manceau, Annette K. Larsen, Dominique Pepin
Publikováno v:
Molecular Oncology
Molecular Oncology, Elsevier, 2016, 10 (8), pp.1221-1231. ⟨10.1016/j.molonc.2016.05.009⟩
Molecular Oncology, 2016, 10 (8), pp.1221-1231. ⟨10.1016/j.molonc.2016.05.009⟩
Molecular Oncology, Elsevier, 2016, 10 (8), pp.1221-1231. ⟨10.1016/j.molonc.2016.05.009⟩
Molecular Oncology, 2016, 10 (8), pp.1221-1231. ⟨10.1016/j.molonc.2016.05.009⟩
International audience; In colorectal cancer (CRC), KRAS mutations are a strong negative predictor for treatment with the EGFR-targeted antibodies cetuximab and panitumumab. Since it can be difficult to obtain appropriate tumor tissues for KRAS genot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5e6cba3d36fcb1ee0ea74524ae0b3bf
https://hal.sorbonne-universite.fr/hal-01331243
https://hal.sorbonne-universite.fr/hal-01331243
Autor:
Denis, Jérôme Alexandre, Patroni, Alexia, Guillerm, Erell, Pépin, Dominique, Benali-Furet, Naoual, Wechsler, Janine, Manceau, Gilles, Bernard, Maguy, Coulet, Florence, Larsen, Annette K., Karoui, Mehdi, Lacorte, Jean-Marc
Publikováno v:
Molecular Oncology; Oct2016, Vol. 10 Issue 8, p1221-1231, 11p
Publikováno v:
Transplant International; Dec2012 Supplement, Vol. 25, p2-76, 74p
Publikováno v:
Transplant International; Dec2012 Supplement, Vol. 25, p47-76, 30p